OUR SCIENCE

Immuno-oncology

We have been early innovators in the field of immuno-oncology. Now, we are building on that expertise to develop current and next-generation immuno-oncology medicines that harness the patient’s immune system to fight cancer. Our active areas of research include:

PATHWAYS UNDER
INVESTIGATION

PD-L1

LEARN MORE

TIGIT

LEARN MORE

TGF-β

LEARN MORE

Abbreviations:
PD-L1, programmed death-ligand 1; TGF-β, transforming growth factor-β; TIGIT, T-cell immunoglobulin and ITIM domain.

Are You a Healthcare Professional?

Yes No